Atlas Trials

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Clinical trial NCT02057159 · UNKNOWN

Trial details

NCT number
NCT02057159
Sponsor
Immune Response BioPharma, Inc.
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Secondary Progress Multiple SclerosisMultiple Sclerosis
Start date
2020-03-09
Primary completion
2023-03-09
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.